ArticleInternational journal of microbiology2012
Experimental models of cryptococcosis.
Article in International journal of microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Blap-6, a Novel Antifungal Peptide from the Chinese Medicinal BeetleInternational journal of molecular sciences · 2024Article
- Preclinical Models for Cryptococcosis of the CNS and Their Characterization Using In Vivo Imaging Techniques.Journal of fungi (Basel, Switzerland) · 2024Review
- A dissemination-prone morphotype enhances extrapulmonary organ entry by Cryptococcus neoformans.Cell host & microbe · 2022Article
- Cryptococcus spp. and Cryptococcosis: focusing on the infection in Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
- Important Mycoses of Wildlife: Emphasis on Etiology, Epidemiology, Diagnosis, and Pathology-A Review: PART 1.Animals : an open access journal from MDPI · 2022Review
- Infections ofFrontiers in cellular and infection microbiology · 2022Article
- Use of Clinical Isolates to Establish Criteria for a Mouse Model of LatentFrontiers in cellular and infection microbiology · 2021Article
- In Vitro or In Vivo Models, the Next Frontier for Unraveling Interactions betweenJournal of fungi (Basel, Switzerland) · 2020Review
- Review
- Animal Models ofFrontiers in immunology · 2020Review
- Innate Immune Responses toJournal of fungi (Basel, Switzerland) · 2017Article
- Inositol Polyphosphate Kinases, Fungal Virulence and Drug Discovery.Journal of fungi (Basel, Switzerland) · 2016Review
- Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal infection.PLoS pathogens · 2015Article
- A multi-host approach for the systematic analysis of virulence factors in Cryptococcus neoformans.The Journal of infectious diseases · 2015Article
- Characterization of the virulence of Cryptococcus neoformans strains in an insect model.Virulence · 2015Article
- Cryptococcus neoformans: historical curiosity to modern pathogen.Yeast (Chichester, England) · 2014Review
- Galleria mellonella model identifies highly virulent strains among all major molecular types of Cryptococcus gattii.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryptococcosis is a life-threatening fungal disease that infects around one million people each year. Establishment and progression of disease involves a complex interplay between the fungus and a diverse range of host cell types. Over recent years, numerous cellular, tissue, and animal models have been exploited to probe this host-pathogen interaction. Here we review the range of experimental models that are available for cryptococcosis research and compare the relative advantages and limitations of the different systems.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.